
US pharma major Bristol Myers Squibb (NYSE: BMY) has signed a broad artificial intelligence partnership with Anthropic, deploying the tech company’s Claude platform across research, clinical development, manufacturing, commercial operations and corporate functions.
The agreement marks one of the most expansive AI rollouts yet by a large drugmaker. More than 30,000 BMS employees will gain access to Claude’s reasoning and “agentic” capabilities, as the company moves beyond basic chatbot tools toward embedding AI into core scientific and operational workflows.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze